Assorted News from the Last Week: A large number of CAC2 members contributed to the recently published conclusions from the 2024 paediatric strategy forum for
In CAC2’s “Fit for Filing” webinar, our speakers explored designing and conducting academic or academic industry collaborative trials that produce data suitable for regulatory filing.
Assorted News from the Last Week: The U.S. Food and Drug Administration (FDA) approved FoundationOne®CDx as a companion diagnostic for Supporting Organization Member Day One
Assorted News from the Last Week: Pope Francis tells pediatric cancer patients they are ‘witnesses of hope.’ Unraveling the relationship between stress exposure and childhood
There were five pieces of legislation that had gained a lot of support across both the House and the Senate over the past two years
During our October federal advocacy drop-in session, we learned about several pieces of legislation that had a good chance to pass before the end of
By CAC2 Individual Member Jennifer Flowers Rhabdomyosarcoma became a common word in my family when I was three years old. By the time of diagnosis,
In conjunction with the European Medicines Agency (EMA), the FDA Oncology Center of Excellence (OCE) held a one-hour Conversations on Cancer public panel discussion on
By CAC2 Student Member Joshua Omale Attending the 2024 International Cancer Week, organized by Nigeria’s National Institute for Cancer Research and Treatment (NICRAT), was indeed
The October 10 Federal Advocacy drop-in session covered three pieces of authorizing legislation and provided an update on possible appropriations for FY2025. Each of the
